---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-017924"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:15:56.537336+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics reports positive GLP tox study for SAB-142; IND submission planned

## Summary
- SAB-142 well tolerated in GLP tox study; NOAEL 10 mg/kg (highest dose).
- SAB-142 modulates key T-cell subsets similarly to rabbit ATG in vivo, confirming mechanism.
- Plans to submit IND for SAB-142 to FDA and initiate Phase 1 trial in coming months.
- Over 8.4M people affected by T1D worldwide; only one disease-modifying treatment available.

## SEC filing metadata
- accession: 0001437749-23-017924
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923017924/0001437749-23-017924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923017924/sabs20230619_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-017924
- JSON: https://secwatch.observer/filing/0001437749-23-017924.json
- Plain text: https://secwatch.observer/filing/0001437749-23-017924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.